Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
-0.75%-1.35%+24.60%+14.36% 227B
-1.60%-3.89%+3.72%-19.20% 146B
-0.85%-1.58%-21.45%+19.12% 130B
+1.81%+2.05%-55.42%-11.25% 69.27B
+0.13%-0.34%+11.07%+16.81% 51.82B
-1.27%-1.43%-18.87%-15.19% 50.45B
+0.59%-1.94%+17.17%+27.91% 42.53B
-1.01%-1.28%+33.64%+50.03% 40.22B
-1.55%+1.22%+120.58%+36.40% 32.95B
Average -0.45%-0.94%+12.78%+13.22% 87.75B
Weighted average by Cap. -0.65%-1.41%+6.57%+8.43%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!